NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Selexis SA , a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have...
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
First IND for NexImmune’s AIM nanoparticle platform in solid tumorsIND clearance enables commencement of a clinical trial to evaluate NEXI-003, an...
NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HONG KONG, Jun 9, 2022 - (ACN Newswire) - On June 8th 2022, Legend Capital's portfolio company ANYCOLOR, a leading Virtual YouTuber (VTuber) management company in Japan, was listed on the Tokyo Stock Exchange....
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND)...
A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment...
GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to...